Edward Aloysius Sullivan Jr. - Nov 9, 2023 Form 4 Insider Report for Comera Life Sciences Holdings, Inc. (CMRA)

Role
Director
Signature
/s/ Ryan M. Rourke Reed, Attorney-in-Fact
Stock symbol
CMRA
Transactions as of
Nov 9, 2023
Transactions value $
$0
Form type
4
Date filed
11/14/2023, 04:32 PM
Previous filing
Sep 1, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CMRA Stock Option (Right to Purchase) Award $0 +127K $0.00 127K Nov 9, 2023 Common Stock 127K $0.32 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Granted pursuant to the Comera Life Sciences Holdings, Inc. 2022 Equity and Incentive Plan. The options were fully vested on the date of grant.
F2 In furtherance of the registrant's cash conservation efforts, the options were granted in lieu of the annual cash retainer and committee fees due to non-employee directors for the quarter ended September 30, 2023, in accordance with the registrant's February 2023 temporary modification to its non-employee director compensation plan. This option was issued to the reporting person in lieu of retainer fees of $16,875. For more information related to the registrant's non-employee director compensation plan and the February 2023 temporary modification, see the registrant's Annual Report on Form 10-K for the year ended December 31, 2022.